Recent advances with insulin degludec for the treatment of Type 2 diabetes

References

• The DCCT Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   PubMedGoogle Scholar
• Riddle MC. The treat to target trial and related studies. Endocr Pract 2006;12(1):71-9
   PubMedGoogle Scholar
• Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1(4):540-8
   PubMedGoogle Scholar
• International Diabetes Federation. IDF treatment algorithm for people with type 2 diabetes. Available from: www.idf.org/sites/default/files/Type%202%20treatment%20algorithm.pdf
   Google Scholar
• American Association of Clinical Endocrinology. AACE comprehensive diabetes management algorithm. 2013. Available from: www.aace.com/files/aace_algorithm.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes. 2008. Available from: http://guidance.nice.org.uk/cg66
   Google Scholar
• Canadian Diabetes Association. Examples of insulin initiation and titration regimes in people with type 2 diabetes. 2013. Available from: http://guidelines.diabetes.ca/Browse/Appendices/Appendix3.aspx
   Google Scholar
• Associazione Medici Diabetologi. Standard Italiani per la cura del diabete mellito tipo 2. 2011. Available from: www.aemmedi.it/files/Lineeguida_Raccomandazioni/2011/AMD_SID_SIMMG_2011.pdf
   Google Scholar
• Philis-Tsimakis A, Brod M, Niemayer M, et al. Insulin degludec once daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther 2013;30(6):607-22
   PubMedGoogle Scholar
• DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23(6):441-54
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6(7):CD006383
   Google Scholar
• Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycaemic episodes on glycaemic and hypoglycaemic management. Can J Diabetes 2005;29(3):00-0
   Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-8
   PubMed Web of Science ®Google Scholar
• McAuley V, Frier BM. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003;4(7):1141-56
   PubMedGoogle Scholar
• Owens DR, Bolli GB. Beyond the era of NPH insulin – long acting insulin analogs: chemistry, comparative pharmacology and clinical application. Diabetes Technol Ther 2008;10(5):333-49
   PubMed Web of Science ®Google Scholar
• Dailey G, Admane K, Mercier F, Owens D. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. 2010;12(12):1019-23
   Google Scholar
• Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. 2003;26(11):3080-6
   Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. 2006;29(6):1269-74
   Google Scholar
• Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra- long acting basal insulin with a unique mechanism of protraction based on multi hexamer formation. Diabetes 2010;59(1):A11
   Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long acting basal insulin. Pharm Res 2012;29(8):2104-14
   PubMed Web of Science ®Google Scholar
• Kurtzahals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose lowering effect of insulin degluec. Diabetologia 2011;54(1):S426
   Google Scholar
• Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14(10):944-50
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26 week, randomised, open-label, parallel group, treat-to-target trial in individuals with type 2 diabetes. Diabetes care 2013;36(4):858-64
   PubMed Web of Science ®Google Scholar
• Tennagels N, Werner U. The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem 2013;119(1):1-14
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1(10):769-83
   PubMed Web of Science ®Google Scholar
• Chisalita SI, Arngvist SJ. Insulin like growth factor 1 receptors are more abundant than insulin receptors in human micro and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004;286(6):E896-901
   Google Scholar
• Hansen BF, Danielsen GM, Drejer K, et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting greater mitogenic potency. Biochem J 1996;315(1):271-9
   PubMedGoogle Scholar
• Nishimura E, Sorensen AR, Hansen BF, et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia 2010;53(1):S388-9
   Google Scholar
• Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16 week, randomised, open label, phase 2 trial. Lancet 2011;377(9769):924-31
   PubMed Web of Science ®Google Scholar
• Zinman B, Philis-Tsimakis A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin naïve patients with type 2 diabetes: a 1 year, randomised, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35(12):2464-71
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Cariou B, Zinman B, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med 2013;30(11):1298-304
   PubMed Web of Science ®Google Scholar
• Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;21:379(9825):1498-507
   Google Scholar
• Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15(2):175-84
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36(9):2536-42
   PubMed Web of Science ®Google Scholar
• Freemantle N, Meneghini L, Christensen T, et al. Insulin degludec improves health-related quality of life (SF-36R) compared with insulin glargine in people with type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med 2013;30(2):226-32
   PubMedGoogle Scholar
• Ericsson A, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16(12):1442-52
   PubMedGoogle Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK healthcare cost perspective. Diabetes Obes Metab 2013. [Epub ahead of print]
   Google Scholar
• Philis-Tsimakis A, Del Prato S, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013;15(8):760-6
   PubMedGoogle Scholar
• Liebl A, Davidson J, Mersebach H, et al. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol 2013;7(5):1328-36
   PubMedGoogle Scholar
• Onishi Y, Ono Y, Rabøl R, et al. Superior glycaemic control with once daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomised controlled phase 3 trial. Diabetes Obes Metab 2013;15(9):826-32
   PubMed Web of Science ®Google Scholar
• Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012;167(2):287-94
   PubMed Web of Science ®Google Scholar
• Heise T, Tack CJ, Cuddihy R, et al. A new generation ultra-long acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomised, controlled trial. Diabetes Care 2011;34(3):669-74
   PubMed Web of Science ®Google Scholar
• Booth HP, Prevost AT, Guilliford MC. Impact of body mass index on prevalence of multimorbidity in primary care: cohort study. Fam Pract 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Teljeur C, Smith SM, Paul G, et al. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract 2013;19(1):17-22
   PubMed Web of Science ®Google Scholar
• Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 2012;771:35-41
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Gough S, Lane W, et al. Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: meta-analysis of 5 randomised BEGIN trial. Endocr Pract 2013;18:1-23. [Epub ahead of print]
   Google Scholar
• Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734-43
   PubMed Web of Science ®Google Scholar
• Kupčová V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig 2013;34:2-127-33
   Google Scholar
• Department of Health. Turning the corner: improving diabetes care. 2006
   Google Scholar
• Department of Health. Improving diabetes services: the NSF four years on. 2007
   Google Scholar
• Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmokinet 2013. [Epub ahead of print]
   Google Scholar
• Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004;21(8):511-30
   PubMed Web of Science ®Google Scholar
• Sorli C, Warren M, Over D, et al. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging 2013;30(12):1009-18
   PubMedGoogle Scholar
• US Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research. Guidance for industry – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
   Google Scholar
• A trial comparing the efficacy and safety of insulin degludec/liraglutide and insulin degludec in subjects with type 2 diabetes (DUAL™ II). Available from: http://clinicaltrials.gov/ct2/show/NCT01392573
   Google Scholar
• Holleman F. Long-acting insulin analogues. 2014. Available from: www.diapedia.org/management/8104096127/long-acting-insulinanalogues
   Google Scholar
• Birkeland K, Home P, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomised controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34:661-5
   PubMed Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamics variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: a randomised controlled trial. J Diabetes Invest 2013;4:4-62-8
   PubMedGoogle Scholar
• Kiss I, Gerhard A, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet 2013;53:2-175-83
   Google Scholar
• Koehler G, Heller S, Korsatko S, et al. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia 2014;57:40-9
   PubMed Web of Science ®Google Scholar
• Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamics profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33(7):515-21
   PubMed Web of Science ®Google Scholar
• Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging 2014;31:47-53
   PubMed Web of Science ®Google Scholar